The psychostimulant methylphenidate (MPH) is increasingly used in the treatment of attention deficit hyperactivity disorder (ADHD). While there is little evidence for common brain pathology in ADHD, some studies suggest a right hemisphere dysfunction among people diagnosed with the condition. However, in spite of the high usage of MPH in children and adolescents, its mechanism of action is poorly understood. Given that MPH blocks the neuronal transporters for dopamine and noradrenaline, most research into the effects of MPH on the brain has largely focused on these two monoamine neurotransmitter systems. Interestingly, recent studies have demonstrated metabolic changes in the brain of ADHD patients, but the impact of MPH on endogenous brain metabolites remains unclear. In this study, a proton nuclear magnetic resonance ( 1 H NMR)-based metabolomics approach was employed to investigate the effects of MPH on brain biomolecules. Adolescent male Sprague Dawley rats were injected intraperitoneally with MPH (5.0 mg/kg) or saline (1.0 ml/kg), and cerebral extracts from the left and right hemispheres were analysed. A total of 22 variables (representing 13 distinct metabolites) were significantly increased in the MPH-treated samples relative to the saline-treated controls. The upregulated metabolites included: amino acid neurotransmitters such as GABA, glutamate and aspartate; large neutral amino acids (LNAA), including the aromatic amino acids (AAA) tyrosine and phenylalanine, both of which are involved in the metabolism of dopamine and noradrenaline; and metabolites associated with energy and cell membrane dynamics, such as creatine and myo-inositol. No significant differences in metabolite concentrations were found between the left and right cerebral hemispheres. These findings provide new insights into the mechanisms of action of the anti-ADHD drug MPH.
Introduction
Attention deficit hyperactivity disorder (ADHD) has become a frequent mental health diagnosis amongst young children and adolescents, and a recent meta-analysis estimates its prevalence to be 3e4% worldwide (Polanczyk et al., 2015) . Symptoms of the disorder include inattention, impulsivity and hyperactivity, which sometimes progress into adulthood Molina et al., 2009) . While the neurobiology of ADHD remains poorly understood, a leading neurochemical theory, which is largely based on the currently known pharmacology of drugs which alleviate disease symptoms, postulates a dysfunctional dopamine system amongst ADHD individuals (Kuczenski and Segal, 2002; Volkow et al., 2007a) . In addition, neurochemical theories of ADHD also implicate the monoamine neurotransmitter noradrenaline (Biederman and Faraone, 2005) , and alterations to more global brain biomolecules such as abnormal creatine, GABA, glutamate, and glutamine levels (Carrey et al., 2007; Jin et al., 2001; Moore et al., 2006; Perlov et al., 2009) . Despite these observed metabolic changes in ADHD patients, the impact of methylphenidate (MPH) treatment on the biochemistry of the brain remains to be established.
Anatomical theories of ADHD indicate a reduced size of the corpus callosum, which leads to insufficient transmission between the two cerebral hemispheres. Some studies also suggest a right hemisphere dysfunction amongst ADHD children (Waldie and Hausmann, 2010) . This hypothesis is supported by the fact that the symptoms of ADHD are similar to those observed amongst patients with right parietal lobe lesions (Voeller and Heilman, 1988) . More recent brain imaging studies also link the behavioural symptoms of ADHD to the smaller and less activated anterior regions of the right cerebral hemisphere when compared to those found on the left side (Stefanatos and Wasserstein, 2001 ). Therefore, in order to identify any potential hemisphere-specific differences involved in the mechanism of action of MPH, samples of both the left and right cerebral hemispheres were investigated in the present study.
The symptoms of ADHD are successfully treated with the psychostimulant methylphenidate (MPH), which blocks the re-uptake of transporter proteins for both dopamine and noradrenaline, thereby increasing their transmission in the synaptic cleft (Kuczenski and Segal, 2002; Volkow et al., 1998) . With an increasing rate of ADHD diagnosis worldwide, a sharp rise in the number of prescriptions of MPH to young children and adolescents has been recorded (Rabiner, 2013) , despite an incomplete understanding of the drug's effects on the adolescent brain. Nonstimulant alternative treatments, such as the noradrenaline reuptake inhibitor atomoxetine, are also often prescribed (Warrer et al., 2016) , and more recently, administration of the aromatic amino acid, tyrosine, a precursor of dopamine and noradrenaline, has also been tested and shown to be effective (Hinz et al., 2011) . Alternatively, the use of exercise as a non-drug treatment paradigm is also recently gaining increasing support, both alone and in combination with MPH (Choi et al., 2015) .
In humans, metabolomics-type studies employing proton magnetic resonance spectroscopy ( 1 H-MRS) is increasingly used for the study of psychiatric disorders and their treatments, including schizophrenia (Marsman et al., 2014) and bi-polar disorders (Brambilla et al., 2005) , together with ADHD (Perlov et al., 2007) . However, 1 H nuclear magnetic resonance ( 1 H NMR) spectroscopic analysis of biofluids and tissues, although related to 1 H MRS, offers higher resolution spectra, in addition to more accurate quantification and greater sensitivity, allowing the detection of less abundant metabolites, including the neurotransmitter GABA . Indeed, 1 H NMR spectroscopy has already been successfully applied to study alterations in human metabolite levels in post-mortem tissue and cerebrospinal fluid collected from patients diagnosed with various psychiatric and neurological disorders (Holmes et al., 2006; Lan et al., 2008; Prabakaran et al., 2004) . Notwithstanding, surprisingly fewer studies have explored drug-inducible metabolic changes in human or animal brain tissues using high-resolution 1 H NMR analysis. Drugs already investigated using this 1 H NMR-linked metabolomics strategy include lithium, antipsychotic drugs, and methamphetamine McLoughlin et al., 2009) . However, to the best of our knowledge, this approach has not yet been applied to determine the effects of MPH on the brain metabolome.
In this study, we have employed, for the first time, a 1 H NMRbased metabolomics approach in order to simultaneously explore the effects of MPH on a wide range of brain metabolites in adolescent rats. We also sought to determine if MPH influences brain metabolites differently in the left and right cerebral hemispheres. The metabolomic, biochemical, therapeutic and physiological significance of the research work performed are discussed in detail.
Materials and methods

Experimental animals
Adolescent male Sprague-Dawley rats weighing 180e200 g were purchased from Charles River (UK). All animals were housed n ¼ 6 per cage under controlled conditions of light (12/12 h lightdark cycle) and temperature (22e25 C, 45% humidity), and allowed free access to food and water. Prior to commencement of the experiments, rats were acclimatised for a period of five days in this environment. All animal experiments in this study were performed in strict accordance with the UK Home Office guidelines and the Animal Scientific Procedures Act (1986). Animals were weighed and randomly assigned to MPH treatment or control groups, with n ¼ 18 animals per group. The rats in the control group were injected intraperitoneally (i.p.) with saline (1.0 ml/kg), whilst the corresponding drug treatment group was injected with MPH (5.0 mg/kg, i.p.). A number of studies have shown that rodents metabolise MPH faster than humans (Aoyama et al., 1996; Balcioglu et al., 2009; Thai et al., 1999) . Therefore, given that this study investigated the acute effect of MPH, a single 5.0 mg/kg MPH dose was administered, since this dose has been shown to reach peak plasma levels similar to a lower dose (i.e. 2.0 mg/kg) in rodents, and also maintains peak levels within the therapeutic range over a longer period (>30 min) compared to that observed with lower doses (Balcioglu et al., 2009; Kuczenski and Segal, 2005) . In accordance with previous studies, it was noted that rats injected with MPH displayed increased locomotion and sniffing compared to the corresponding controls (Appenrodt and Schwarzberg, 2003) . Rats were killed one hour after their injections, i.e. when behavioural activation had ceased in the treatment group. Animals were then sacrificed by rapid dislocation of the neck, followed by removal of the brain. The left and right cerebral hemispheres were rapidly dissected, snap-frozen in isopentane on dry ice, and stored individually at À80 C until required for 1 H NMR analysis.
Preparation of brain extracts for 1 H NMR analysis
The extraction procedure used was a minor modification of that described by Waters et al. (2002) . Frozen tissue samples were weighed prior to subjecting them to mechanical homogenisation in equivalent volumes of acetonitrile and HPLC-grade water (i.e., a 4.00 ml volume per gram of tissue) using an electric pestle rotor (Sigma-Aldrich UK). The resultant homogenates were retained on ice for a period of 30 min and then centrifuged at 10,000xg for 10 min at 4 C. The upper 1:1 (v/v) aqueous/acetonitrile phase of each sample was then removed and lyophilised. The residue for each sample was subsequently reconstituted with 50 ml of 1.00 M sodium phosphate buffer (pH 7.0) and 550 ml of deuterium oxide ( 2 H 2 O) containing 0.9 mM sodium 3-trimethylsilyl-(2,2,3,3-H 2 H 4 )- were employed in order to confirm these assignments. HSQC spectra were acquired using the hsqcedetgpsp.3 pulse sequence (TOPSPIN version 3.0, Bruker Biospin), and 128 scans with 128 increments were acquired for each spectrum. Spectra were collected with 2048 points in t 2 , and 256 points in t 1 , over a sweep width of 66,000 and 4800 Hz and in F1 and F2, respectively. 1 H-1 H COSY NMR spectra were acquired using the cosygpprqf pulse sequence (TOPSPIN version 3.0, Bruker Biospin), recording 48 scans. The spectral width was 4800 Hz. In addition, the statistical total correlation spectroscopy (STOCSY) technique was applied for the resolution and identification of selected signals such as those of hypoxanthine, and using the option available in the MUMA R package (Cloarec et al., 2005; Gaude et al., 2013 ).
Multivariate and univariate statistical analyses
Multivariate and univariate statistical analyses were performed on sample mass-and TSP-normalised integral values. Both Principal Component Analysis (PCA) and Partial Least SquaresDiscriminant Analysis (PLS-DA) were performed using MetaboAnalyst 3.0 (Xia et al., 2015) , a web-based metabolomics data analysis resource. PLS-DA was conducted for the discrimination of drug treatment and control classifications, together with biomarker identification. The default 10-fold cross validation strategy was applied in order to guard against model overfitting. In general, a quality assessment statistic (Q 2 ) ! 0.4 is considered as a reliable model, as previously described (McLoughlin et al., 2009; Worley and Powers, 2013) . Prior to any multivariate and univariate analysis, the dataset was cube root-transformed and Pareto-scaled in order to satisfy assumptions of normality and homoscedasticity, which are required for the satisfaction of assumptions for the parametric tests performed. To explore performance of the different subsets and the combination of discriminatory metabolites selected by PLS-DA as above, a ROC curve analysis was conducted using the Biomarker Analysis option available in MetaboAnalyst 3.0. Multivariate paired sample comparisons between the left-and right-brain hemispheres of experimental animals were made using the single factor, paired sample option of MetaboAnalyst 3.0. Further validation was performed with XLSTAT2016, which employed permutation testing via partial redundancy analysis (P-RDA), with 'cerebral hemisphere' as the 'conditioning' variable, and 5 Â 10 3 permutations.
Univariate analysis was also carried out using an ANOVA (analysis-of-variance) experimental design (performed with the corresponding function in R 3.1.2 statistical software) in which 2 factors and 3 primary sources of variation were incorporated: (1) 'treatment status' (i.e. MPH-treated vs. control rats, T i ); (2) 'between-cerebral hemispheres' (i.e. left vs. right hemispheres, H j ), and (3) the 'treatment status' x 'cerebral hemisphere' interaction effect (TH ij ). This experimental design is represented by equation (1), in which Y ij represents the (univariate) response variable values observed, m its overall population mean value in the absence of any significant sources of variation, and e ij the unexplained error (residual) contribution. The significance (p-value) of each of these components of variance was adjusted for the performance of multiple comparisons using the False Discovery Rate (FDR) correction criteria.
Simultaneous MV analysis of the main MPH 'treatment status' and 'cerebral hemisphere' variables was conducted using ANOVA simultaneous component analysis (ASCA), i.e., via the two-factor independent samples option of MetaboAnalyst 3.0 (which is based on equation (1)) in order to detect any significant major metabolic patterns arising from each experimental factor, including the MV TH ij interaction component of variance. The significance of each of these MV variance components was determined via associated permutation testing with 1000 permutations. In addition, the statistical significance of any biomolecular differences between the left and right cerebral hemispheres was further investigated in a MV manner using the single-factor paired analysis option of MetaboAnalyst 3.0. A range of MV statistical evaluations were performed for these comparisons, including PCA and PLS-DA involving further cross-validation and permutation testing.
Retrospective MV power analysis calculations
The minimum sample sizes required to achieve MV statistical significance between the MPH-treated and saline-treated control groups were retrospectively determined by applying the Power Analysis option of MetaboAnalyst 3.0 to a dataset consisting of 13 key biomarker variables discovered via PLS-DA analysis (i.e. GABA, alanine, aspartate, creatine, phosphocholine, hypoxanthine, myoinositol, glutamate, lysine, taurine, valine, phenylalanine and tyrosine, Table 1 ). With an FDR-adjusted p value of only 0.005, predicted MV test powers of 0.99 and 1.00 were calculated for sample sizes of 16 and 24 per group (Fig. 1) , and this clearly confirms that the sample sizes selected (i.e. n ¼ 18 rats/group) for this biomarker variable-optimised NMR-linked metabolomics study was indeed sufficient.
Metabolite set enrichment and metabolic pathway analysis
Detailed analysis of the most relevant cerebral metabolic pathways and networks invoked as respondents to MPH treatment was performed using the MetaboAnalyst 3.0 tool (Xia et al., 2015) . This web-based facility employs high-quality Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways as the structured back-end knowledge base, and integrates a series of now wellestablished methods (i.e., univariate and over-representation analyses), together with novel algorithms and concepts (i.e., Global Test, Global-ANCOVA, and Network Topology Analysis) with pathway analysis. For this dataset, we employed the Global ANCOVA and Relative-Betweeness Centrality algorithm for metabolic pathway and topological analyses, the latter serving as a key measure indicating the importance of a graph node when expressed relative to that of the others (Aittokallio and Schwikowski, 2006) . For the pathway topology analysis performed, the Rattus norvegicus (rat) mammalian pathway library was selected. This approach was also utilised to provide estimates of H NMR spectra acquired on the aqueous cerebral extracts from both saline-treated controls and the MPH-treated rats are shown in Fig. 2 . These spectra contained a large number of prominent resonances assignable to a wide range of low-molecular-mass metabolites, including amino acids (e.g., alanine, aspartate, GABA, lysine, tyrosine and phenylalanine), organic acid anions (acetate, formate, lactate, etc.), creatine, phosphocreatine and myo-inositol, together with purines and pyrimidines and their nucleoside adducts (hypoxanthine, inosine, etc.), as well as nicotinate and nicotinamide pathway adducts. A preliminary evaluation of the spectral profiles revealed MPH-induced changes of the levels of amino acid neurotransmitters (e.g. GABA, glutamate and aspartate), large neutral amino acids (e.g. tyrosine, phenylalanine, lysine, alanine, and valine), water-soluble membrane components (e.g. phosphocholine, myo-inositol), energy-related metabolites (e.g. creatine), and purine derivatives (e.g. hypoxanthine).
Classification of brain extract 1 H NMR profiles according to their treatment status
Of the 113 ISB variables investigated, 103 had higher mean values for the MPH-treated group when expressed relative to those of the control group (i.e. 103 positive fold-changes), while 10 of the ISB variables had lower mean values for the MPH-treated group relative to the controls (i.e. 10 negative fold-changes). Primarily, PLS-DA was employed to analyse the 1 H NMR dataset in order to classify the samples according to their treatment status. The 3D scores plot for the first three components showed that the MPHtreated cerebral regions can be clearly distinguished from the saline-treated controls (Fig. 3A) . To evaluate the performance of class discrimination, a permutation test was conducted with 2000 permutations, where the ratio of the between-sum-of-squares to the within-sum-of-squares (B/W-ratio) for the class assignment prediction of each model was computed, and this yielded a p-value of 5 Â 10 À4 , indicating a strong discrimination between the MPHand saline-treated control groups. A PC1 vs. PC2 variable loadings plot obtained from PCA analysis (Supplementary Information: Fig. S1 ) of our experimental data revealed that the former PC represented the component most responsible for discrimination between the two classifications. Specifically, both phenylalanine and tyrosine (clearly linked as features of the phenylalanine metabolism pathway) had low positive PC2 scores vectors, and low-to-high positive PC1 ones. Moreover, myo-inositol, phosphocholine, taurine, aspartate and glutamate were clustered together somewhat, each with higher positive PC2 but negative PC1 loadings, whereas valine, lysine, alanine, and especially GABA, had high positive PC2 but low-tointermediate positive PC1 ones (data not shown). Since both GABA and glutamate are involved in a series of the pathways featured in the quantitative topological pathway analysis conducted (outlined below), they are at least partially isolated from clusterings of the other biomarker predictor variable features observed, as expected.
MPH-induced metabolic alterations in brain samples
Treatment of experimental animals with MPH was found to significantly alter the metabolic profiles of rat cerebrum (Fig. 3) 
ROC curve analysis
ROC curve analysis provides a graphical view of the degree to which the discriminant metabolites are successfully classified into one of the two groups explored, based on their treatment status (i.e. either MPH-or saline-treated). Here, a maximum of 13 discriminant metabolites (selected from the top 22 ISB variables: Table 1 ) that were identified from the PLS-DA analysis were employed for this ROC curve analysis. Selection was based on variable rankings, and therefore in cases where two or more ISB variables arising from the same metabolite were selected as discriminatory features, only the highest ranked ISB variable was included in the analysis. The 13 variables included in the ROC curve analysis were GABA-C3-CH 2 (1.85e1.95 ppm), valine-C4-CH 3 (0.91e1.00 ppm), myo-inositol-C3-CH 2 (3.51e3.58 ppm), alanine-C3-CH 3 (1.45e1.53 ppm), lysine-C5-CH 2 (1.66e1.75 ppm), hypoxanthine-C7-CH (8.21e8.23 ppm), phosphocholine/glycero-phosphocholine-N þ (CH 3 ) 3 (3.21e3.25 ppm), aspartate-C3-CH 2a (2.73e2.81 ppm), phenylalanine-b-CH 2 (3.08e3.13 ppm), taurine-C1-CH 2 (3.39e3.48 ppm), glutamate-C4-CH 2 (2.33e2.39 ppm), tyrosine-C6-CH (7.16e7.23 ppm), and phosphocreatine (3.92e3.96 ppm). The ROC curve in Fig. 3B shows the AUROC range values for the metabolites included. Overall, this analysis indicates a good discrimination between the MPH-treated and control groups (mean AUROC value > 0.8), which provides further evidence that the two treatment groups differed significantly in terms of their 1 H NMR metabolic profiles.
Multifactorial MV ASCA and P-RDA approaches
The 'treatment status' and 'between-cerebral hemispheres' variance components were simultaneously explored using an ASCA two-factor independent sample analysis option. No significant differences were observed for the 'between-cerebral hemispheres' factor after performing this analysis (i.e. p > 0.05). Furthermore, the 'treatment status x cerebral hemisphere' interaction component of variance was also found not to be significant for the first two (major) principal components explored (p > 0.05). However, as expected, the 'treatment status' factor was indeed significant (p ¼ 0.006). In addition, the P-RDA approach, which excluded any contributory effects exerted by the qualitative cerebral hemisphere 'conditioning' variable confirmed the significance of the 'treatment status' factor (p ¼ 0.0042). This strategy was also applied to explore the contribution of the 'cerebral hemisphere' factor (by excluding the 'treatment-status' 'conditioning' variable), and this analysis revealed that the 'between-hemispheres' factor was indeed not significant (p ¼ 0.66). GABA, g-aminobutyric acid; NAA, N-acetylaspartate; NAAG, N-acetylaspartylglutamate; Glu, glutamate; Gln, glutamine; Chol, choline; PChol, phosphocholine; GPChol, glycerolphosphocholine; NAD, nicotinamide adenine dinucleotide.
Exploration of differences between right and left cerebral hemispheres
The paired option PLS-DA analysis performed on the dataset using cerebral hemisphere as a response variable showed no significant differences between the left and right ones for both the MPH-treated and the control rats. In both cases, the maximum accuracy value was 0.54 for a model containing 3 components, and Q 2 attained values were 0.1. Additionally, the p-value obtained from the permutation test (2000 permutations) was nonsignificant (p ¼ 0.44). The ANOVA analysis performed also did not reveal any significant differences between the two cerebral hemispheres, and the 'cerebral hemisphere x treatment status' interaction effect was also not significant. Similarly, as noted above, the ASCA strategy performed on the complete ISB variable dataset failed to detect any differences between the two cerebral hemispheres.
Quantitative network metabolic pathway analysis
Quantitative network pathway analysis involving pathway enrichment analysis and pathway impact from pathway topology (Xia et al., 2012 (Xia et al., , 2015 revealed highly statistically-significant MPHinduced modulations to a series of metabolic pathways. The pathways with the greatest metabolic impact were tyrosine biosynthesis > alanine, aspartate and glutamate metabolism > taurine and hypotaurine metabolism > phenylalanine metabolism > tyrosine metabolism > arginine and proline metabolism. Pathway impact indices, together with false discovery rate (FDR)-adjusted p-values (computed from a quantitative comparison of the MPH-treatment and saline control groups performed on the full dataset), are also listed in Table 2 .
Discussion
The psychostimulant drug, MPH, is increasingly used for the treatment of ADHD symptoms in children, despite the limited knowledge available regarding its effects on the developing brain. Here, we provide some novel insights into the metabolic mechanisms of action of this drug on the adolescent brain. For this purpose, 1 H NMR-linked metabolomics analysis was employed for the analysis of cerebral samples. Given the heterogeneity of ADHD symptoms, and the fact that no common brain pathology or gene defect of the condition has been identified, we employed normal animals in this metabolomics study. Indeed, the proposed animal models of ADHD, which range from those with neurotoxic lesions to genetically-manipulated animals, are likely to reflect some of the disease symptoms rather than the full neurobiological basis of the disorder (Sontag et al., 2010) . To the best of our knowledge, this is the first investigation that has employed 1 H NMR-linked metabolomics analysis to assess brain tissues from adolescent rats treated with this anti-ADHD drug. 
MPH increases amino-acid neurotransmitter levels
One major finding in the present study is the increased level of GABA in cerebral extracts collected from adolescent rats treated with MPH relative to those of corresponding saline-treated controls (Table 1) . Compared to the high number of clinical and pre-clinical studies addressing the involvement of monoamines (in particular dopamine) in the symptoms and treatment of ADHD, previous investigations of the primary brain inhibitory neurotransmitter GABA in ADHD are limited and inconsistent. A previous study using in vivo magnetic resonance spectroscopy (MRS) reported diminished GABA concentrations in sensorimotor cortex in children diagnosed with ADHD (Edden et al., 2012) . However, a more recent study, which explored different parts of the brain (including the subcortical regions), demonstrated developmental changes in GABA levels in ADHD, with an increase observed in adults but no changes notable in children (Bollmann et al., 2015) .
The enhancement of GABA levels following MPH treatment observed in this study is likely to indicate a general enhancement of inhibitory neurotransmission, and is supported by an earlier electrophysiological study which demonstrated that MPH increases GABAergic neurotransmission in the sensory thalamic nuclei of rat cerebrum (Goitia et al., 2013) . Given that MPH's ability to block monoamine transporters is well established (a process leading to increased extracellular levels of the excitatory transmitters dopamine and noradrenaline), the link between this effect and increased whole tissue levels of GABA remains somewhat unclear. The upregulated GABA levels are, however, not unique to MPH, since previous animal studies using high-resolution 1 H NMR analysis have detected similar effects following both single and repeated injections of the anti-manic drugs lithium (Li þ ) and carbamazepine (Lan et al., 2008; McLoughlin et al., 2009) . Importantly, the Li þ -induced enhancement of GABA levels was replicated in human brain tissues (Lan et al., 2008) . In contrast, a range of antipsychotic drugs failed to increase GABA levels in rat brain, an observation indicating that this effect does not appear to be a general one observed with all brain-active amphiphilic drugs (McLoughlin et al., 2009 ). This study also detected enhanced levels of glutamate and aspartate in brain samples from MPH-treated rats when compared to those of the saline-treated control group (Table 1 ). Since it is well known that GABA is generated from glutamate in GABAergic neurons via glutamic acid decarboxylase, it is possible that elevated glutamate levels may indeed be related to our finding of MPHinduced GABA level enhancement. Consistent with this postulate, a corresponding PCA revealed that the ISBs containing all 3 of GABA's 1 H NMR resonances (see Table 1 ) were found to be strongly and positively loaded (loading scores 0.93e0.96) on the same principal component as that of the glutamate's C4-CH 2 signal (loading score 0.93). In addition, glutamatergic abnormalities have also been implicated in the pathophysiology of ADHD (Moore et al., 2006) , and anti-ADHD drugs such as MPH modulate glutamate neurotransmission in rodents, and also modulate glutamate receptor function, long-term potentiation (LTP), and cognition (Chen et al., 2015; Di Miceli and Gronier, 2015; Rozas et al., 2015; Schmitz et al., 2016) . Given that glutamate is stored in both neuronal and glial cells, it is however, unclear if our finding of MPH-induced elevation of whole tissue levels of glutamate is related to an enhanced level of excitatory neuronal transmission. Brain levels of aspartate and taurine were also enhanced by MPH in this study. The non-essential amino acid aspartate, like glutamate, is stored in both glia cells and neurons. Indeed, some studies have suggested vesicular co-storage of glutamate and aspartate (Morland et al., 2013) . Based on the fact that aspartate acts as a full agonist on glutamatergic NMDA (N-methyl-Daspartate) receptors, it has been proposed that it also acts as a cotransmitter with glutamate in excitatory synapses (Morland et al., 2013; Patneau and Mayer, 1990) . Such a role for aspartate has, however, recently been contested (Herring et al., 2015) . The enhancement of taurine in brain samples of rats treated with MPH could also be of much neurochemical importance. Taurine is one of the most abundant amino acids in the brain, and is involved in a variety of brain functions including cytoprotection and brain development (Ripps and Shen, 2012) . The chemical structure of taurine is similar to GABA, and it acts as an agonist on the GABA B receptor (Kontro and Oja, 1990) , as well as on the glycine site of the NMDA receptor (Chan et al., 2014) . MPH is known to enhance monoamine function, and this effect is associated with the drug's ability to promote LTP (Jenson et al., 2015) . In this regard, it is interesting to note that previous studies have shown that taurine affects dopamine release, and together with dopamine D1 activation promotes LTP, an NMDA receptor-dependent mechanism (Salim€ aki et al., 2003; Su arez et al., 2014) . Hence, it is possible that the MPH-induced upregulation of brain tissue levels of both taurine and aspartate, observed in this study, may be involved in MPHinduced LTP (Jenson et al., 2015) .
MPH increases brain levels of large neutral amino acids
The present study also demonstrated significant MPH-induced upregulations of some large neutral amino acids (LNAA), including the AAAs tyrosine and phenylalanine, in addition to the branched-chain amino acid (BCAA) valine. However, these LNAAs are all polar compounds and cannot cross the blood-brain barrier (BBB) freely. In order to enter the brain from blood plasma, they alternatively utilise an active transport system, the large neutral amino acid transporter LAT-1 (Fernstr€ om, 2013) . Different types of LNAAs compete with each other for transport from plasma to brain via the LAT-1 system, and it cannot be excluded that MPH may indeed modify the physiological balance of LNAAs in plasma, a process that may favour the entry of some of them into the brain over others (Fernstr€ om and Fernstr€ om, 2007) . In this study, adolescent rats were treated with a dose of MPH (5.0 mg/kg, i.p.), which gives rise to pronounced behavioural activation including increased locomotion, sniffing and rearing. It may therefore be speculated that such an MPH-induced increase in motor activity enhances the plasma to brain transport of selected LNAAs, including tyrosine and its precursor, phenylalanine. In support of this, rats exposed to treadmill running show increased brain levels of tyrosine (Acworth et al., 1986) . Similar to the findings on MPH in this study, another psychostimulant, d-amphetamine, which is also used in ADHD treatment, has been shown to increase rat brain levels of LNAAs, including tyrosine (Fernando and Curzon, 1978) . Possible contributing factor for a psychostimulant-induced upregulation of brain levels of LNAAs may include their known body temperature-escalating action (i.e. increasing body temperature increases metabolism), which has been observed in both animals and humans (Fernando and Curzon, 1978; Hetzler et al., 2014) .
Dysfunctional neurotransmission of the dopamine and noradrenaline systems are implicated in the symptoms of ADHD, and these catecholamines play important roles in the control of motor activity and executive brain function (Del Campo et al., 2011) . Further, both animal and clinical studies clearly demonstrate that MPH blocks the presynaptic transporters for dopamine (DAT) and noradrenaline (NET), and thereby increase extracellular levels of these catecholamines (Berridge et al., 2006; Kuczenski and Segal, 2002; Volkow et al., 1998) . In this study, we have demonstrated that MPH significantly increased levels of the AAA tyrosine and its precursor phenylalanine, in the brain of MPH-treated adolescent rats over those of corresponding saline-treated rats (Table 1) .
Tyrosine functions as a precursor for both dopamine and noradrenaline in the brain, and unlike other neurotransmitter biosynthetic pathways, the rates of synthesis of dopamine and noradrenaline are sensitive to local substrate concentrations, particularly in the ranges normally found in vivo. Consequently, ex vivo factors such as diet and exercise that enhance the brain pool of tyrosine also increase the rate of conversion of this biomolecule into dopamine and noradrenaline in their respective nerve terminals, ultimately elevating their synaptic concentrations (Fernstr€ om and Fernstr€ om, 2007) . In contrast, when tyrosine transport into the brain is suppressed by the administration of a tyrosine/ phenylalanine-free LNAA mixture, the physiological-and amphetamine-evoked release of dopamine in rodents is impaired (Le Masurier et al., 2013; McTavish et al., 2001) . Similarly, dietary tyrosine/phenylalanine depletion in humans attenuates rewardrelated behaviour, which is driven by dopamine (Bjork et al., 2014) .
The MPH-induced increase of brain tyrosine levels may indeed be relevant to recent neuropsychological studies reporting that tyrosine-free amino acid mixtures disrupt performance in a range of behavioural and cognitive tasks that are dependent on dopamine and noradrenaline levels (Coull et al., 2012) . Also of interest to this study is a recent clinical finding which demonstrates that administration of tyrosine-rich amino acid mixtures effectively diminish ADHD symptoms in some children (Hinz et al., 2011) . Therefore, it is possible that MPH alleviates ADHD symptoms in two manners: (1) via blockage of DAT and NET, and (2) by enhancing the brain pool of tyrosine and phenylalanine as demonstrated here.
In addition, brain levels of the non-essential amino acid alanine were significantly higher in the MPH-treated rats when compared to that of corresponding controls. Alanine is involved in glucose generation, and can be manufactured in the body from the BCAA valine, which as noted above was also upregulated by MPH in this study. Although the brain is not normally associated with glycogenesis, some previous data suggest that this might indeed be the case; however, this is much less efficient than that occurring hepatically (Bhattacharya and Datta, 1993) . Moreover, brain levels of the essential amino acid lysine were also found to be significantly elevated in MPH-treated rats. Although the direct functional impact of this effect is not yet clear, lysine has been reported to block serotonin receptors, and a reduced lysine intake is associated with anxiety, a symptom occasionally coinciding with ADHD (Mulraney et al., 2016; Smriga et al., 2002) .
MPH alters energy metabolism
Previous studies have suggested that MPH alters brain energy metabolism. Specifically, the drug has been shown to alter cerebral glucose utilisation (Porrino and Lucignani, 1987) , and serves to increase the uptake of this biomolecule in the brain of both young and adult rats (R eus et al., 2015) . In the present study, we detected a significant MPH-induced upregulation of creatine levels in the cerebrum (Table 1) . It is possible that this finding is related to an earlier study showing that MPH (2.0e10.0 mg/kg) increases creatine kinase activity in several regions of rat cerebrum, including the prefrontal cortex, hippocampus, and striatum, all of which are implicated in the mechanism of action of MPH (Scaini et al., 2008) . Creatine kinase catalyses the transfer of a phosphoryl group from adenosine triphosphate (ATP) to creatine, producing PCr and adenosine diphosphate (ADP). This reaction is, of course, reversible, and hence creatine kinase may play an important role in the rapid regeneration of ATP in high energy-consuming tissues such as the cerebrum. Furthermore, MPH is known to elevate neuronal activity, which is evident from its ability to increase the transcription of several activity-dependent genes, together with their corresponding proteins (Banerjee et al., 2009; Gronier et al., 2010; Yano and Steiner, 2007) , and it is likely that this effect is dependent on a local elevated level of ATP metabolism. Although it is not possible to establish the precise mechanism behind the MPH-induced elevation of creatine levels in this study, it is likely that this effect is related to the known the blockade of DAT by MPH, which increases synaptic dopamine levels and hence dopamine receptor stimulation. In support of this, antipsychotic drugs known to block dopamine receptors reduce creatine kinase activity and creatine levels in the brains of rats and humans, respectively (Assis et al., 2007; Sarramea Crespo et al., 2008) .
In addition to the creatine/phosphocreatine cycle, purine metabolism is also closely linked to ATP production and utilisation. Here, we found that the purine derivative, hypoxanthine, was significantly enhanced in the cerebrum of the MPH-treated rats relative to controls (Table 1 ). This could give rise to increased levels of the final metabolite of purine catabolism, urate. Indeed, like MPH, d-amphetamine, which also increases synaptic levels of dopamine and is employed in the treatment of ADHD, has been shown to increase brain levels of this metabolic product (Miele et al., 2000) .
MPH and membrane-related metabolites
Brain levels of myo-inositol were also significantly increased following MPH administration (Table 1 ). This metabolite is abundant in both neurons and glial cells, and is known to serve as a marker of membrane turnover, as well as glial cell integrity (Brand et al., 1993) . In contrast to the present finding, other psychoactive drugs, including antipsychotic drugs, Li þ and valproate, have been found to reduce brain levels of myo-inositol in both animal and human studies (Lan et al., 2008; McLoughlin et al., 2009) . Additionally, phosphocholine is a known precursor of various membrane phospholipids in both glial cells and neurons (Paoletti et al., 2011) . Significantly increased concentrations of this metabolite were also noted in MPH-treated brain samples, and this may indicate that altered lipid turnover rate may be involved in the action of the drug. Taken together, the enhancement of phosphocholine and myo-inositol by MPH could indicate that the drug acutely alters the dynamics of cerebral cell membranes.
Comparisons of the two cerebral hemispheres
Some studies have previously suggested a right hemisphere dysfunction in ADHD (Waldie and Hausmann, 2010) . Consequently, this study sought to establish if MPH influences brain metabolites differentially in the right and left cerebral hemispheres. However, both paired multivariate and univariate statistical approaches employed for this purpose failed to detect any significant metabolic differences between these two cerebral hemispheric groups.
Relevance to the pathophysiology and treatment of ADHD
While the pathophysiology of ADHD remains poorly understood, a leading neurochemical theory based on both preclinical and clinical studies, postulates dysfunctional dopamine and noradrenaline systems as major factors underlying the symptoms ADHD (Biederman and Faraone, 2005; Kuczenski and Segal, 2002; Volkow et al., 2007b) . In support of this theory, MPH blocks neuronal reuptake of both dopamine and noradrenaline (Del Campo et al., 2011) . Given that MPH increased cerebral levels of the precursors of catecholamine synthesis namely, phenylalanine and tyrosine, the findings of the present study further strengthen the catecholamine theory of ADHD. In line with this, a previous clinical study indeed found that the administration of tyrosine-rich amino acid mixtures effectively diminish ADHD symptoms in some affected children (Hinz et al., 2011) . In addition to the catecholamine theory of ADHD, abnormalities of amino acid neurotransmission have also been suggested to be involved in ADHD. In particular, deficits in glutamate and GABA levels have been reported in some cerebral areas of ADHD patients (Edden et al., 2012; Perlov et al., 2007) , although not all studies have found this (Bollmann et al., 2015) . Thus, the MPH induced increase of glutamate and GABA levels shown in the present study may be of clinical relevance in correcting the abnormal levels of these amino acid neurotransmitters as previously observed in ADHD patients.
Secondary to the dysfunctional neurotransmitter theories of ADHD, it has also been hypothesised that some of the symptoms of ADHD may arise as a result of reduced astrocytic energy metabolism (Russell et al., 2006) . Specifically, impaired energy production may decrease performance in some motor and cognitive tasks (Killeen et al., 2013; Russell et al., 2006) . Therefore, our finding of MPH-induced increase of the energy-related metabolite creatine could enhance cerebellar ATP regeneration and hence aid in the accomplishment of tasks demanding high-energy levels. Based on the results of the present study, we suggest that in addition to DAT and NET blockade, acute MPH treatment may also alleviate the symptoms of ADHD via the following mechanisms: 1) by an enhancement of the brain pool of the catecholamine precursor tyrosine 2) by an upregulation of the amino acid neurotransmitters glutamate and GABA 3) by an elevation of creatine and energy metabolism in the cerebrum.
Conclusions
This study was aimed at detecting MPH-induced alterations of multiple cerebral metabolites in order to improve our understanding of the mechanisms of action of this drug in the adolescent brain following acute treatment. Our results indicated that MPH significantly increased several rat cerebral metabolites, including amino acid neurotransmitters such as GABA and glutamate, and also upregulated LNAAs such as tyrosine and its precursor phenylalanine. The present study also indicated that a single administration of MPH alters membrane and energy metabolism in the cerebrum. The acute effects of MPH observed in the present study could be related to the mechanism of action of the drug in the adolescent brain, and also in alleviating ADHD symptoms. It will be important for future studies to investigate the effect of MPH in distinct brain regions that are implicated in the symptoms of ADHD, as well as the persistence of its observed effects following chronic administration.
